CREDENCE: Significant Victory for Diabetic Kidney Disease

Diabetic kidney disease (DKD), the most common cause of end-stage kidney disease (ESKD), has significant morbidity and mortality, particularly from cardiovascular complications. The CREDENCE ( canagliflozin and renal events in diabetes with established nephropathy clinical evaluation) trial reported by Perkovic and collaborators has led to an emergence of a new class of therapeutic agents for slowing DKD progression.